BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have lower risk MDS. METHODS: The authors retrospectively evaluated 74 patients with International Prognostic Scoring System low-risk or intermediate I-risk MDS, who received azacitidine on a national named patient program. At baseline, 84% of patients were transfusion-dependent, 57% had received erythropoietin, and 51% were aged >70 years. Azacitidine was administered subcutaneously for 5 days (n = 29 patients), 7 days (n = 43 patients), or 10 days (n = 2 patients) every month at a dose of 75 mg/m(2) daily (n = 45 patients) or at a fixed dose of 100 mg daily (n = 29 patients) and for a median of 7 cycles (range, 1-30 cycles). RESULTS: According to the 2006 International Working Group criteria, overall response rate (ORR) was 45.9%, including complete responses (10.8%), partial responses (9.5%), hematologic improvements (20.3%), and bone marrow complete responses (5.4%). The ORR was 51.6% in 64 patients who completed >= 4 cycles of treatment. The median duration of response was 6 months (range, 1-30 months). After a median follow-up of IS months, 71% of patients remained alive. A survival benefit was observed in responders versus nonresponders (94% vs 54% of patients projected to be alive at 2.5 years, respectively; P < .0014). The most common grade 3 or 4 adverse events were myelosuppression (21.6%) and infection (6.8%). CONCLUSIONS: The current results indicated that azacitidine may be a feasible and effective treatment for patients with lower risk MDS.

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program / Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F., Lunghi, M., Villani, O., Aloe-Spiriti, M.A., Venditti, A., Santini, V., Leone, G., Voso, M.T., D'Arco, A.M., Tatarelli, C., Ferrero, D., Gaidano, G., Palumbo, G., Di Raimondo, F., Oliva, E., Sanpaolo, G., Tonso, A., Santagostino, A., Filardi, N., Pollio, B., Candoni, A., Fili, C., Russo, D., Orciuolo, E., Petrini, M., Ciuffreda, L., Riezzo, A., Morabito, F., Mazza, P., Pastore, D., Specchia, G., Ferrara, F.. - In: CANCER. - ISSN 1045-7410. - ELETTRONICO. - 116:(2010), pp. 1485-1494. [10.1002/cncr.24894]

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

Santini V.;
2010

Abstract

BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have lower risk MDS. METHODS: The authors retrospectively evaluated 74 patients with International Prognostic Scoring System low-risk or intermediate I-risk MDS, who received azacitidine on a national named patient program. At baseline, 84% of patients were transfusion-dependent, 57% had received erythropoietin, and 51% were aged >70 years. Azacitidine was administered subcutaneously for 5 days (n = 29 patients), 7 days (n = 43 patients), or 10 days (n = 2 patients) every month at a dose of 75 mg/m(2) daily (n = 45 patients) or at a fixed dose of 100 mg daily (n = 29 patients) and for a median of 7 cycles (range, 1-30 cycles). RESULTS: According to the 2006 International Working Group criteria, overall response rate (ORR) was 45.9%, including complete responses (10.8%), partial responses (9.5%), hematologic improvements (20.3%), and bone marrow complete responses (5.4%). The ORR was 51.6% in 64 patients who completed >= 4 cycles of treatment. The median duration of response was 6 months (range, 1-30 months). After a median follow-up of IS months, 71% of patients remained alive. A survival benefit was observed in responders versus nonresponders (94% vs 54% of patients projected to be alive at 2.5 years, respectively; P < .0014). The most common grade 3 or 4 adverse events were myelosuppression (21.6%) and infection (6.8%). CONCLUSIONS: The current results indicated that azacitidine may be a feasible and effective treatment for patients with lower risk MDS.
2010
116
1485
1494
Goal 3: Good health and well-being for people
Musto, P., Maurillo, L., Spagnoli, A., Gozzini, A., Rivellini, F., Lunghi, M., Villani, O., Aloe-Spiriti, M.A., Venditti, A., Santini, V., Leone, G., Voso, M.T., D'Arco, A.M., Tatarelli, C., Ferrero, D., Gaidano, G., Palumbo, G., Di Raimondo, F., Oliva, E., Sanpaolo, G., Tonso, A., Santagostino, A., Filardi, N., Pollio, B., Candoni, A., Fili, C., Russo, D., Orciuolo, E., Petrini, M., Ciuffreda, L., Riezzo, A., Morabito, F., Mazza, P., Pastore, D., Specchia, G., Ferrara, F.
File in questo prodotto:
File Dimensione Formato  
LR-MDSMusto.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 202.82 kB
Formato Adobe PDF
202.82 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/387125
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 95
  • ???jsp.display-item.citation.isi??? 78
social impact